Eekhoff E W M, Karperien M, Houtsma D, Zwinderman A H, Dragoiescu C, Kneppers A L J, Papapoulos S E
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Arthritis Rheum. 2004 May;50(5):1650-4. doi: 10.1002/art.20224.
To estimate the occurrence of familial Paget's disease of bone in The Netherlands, to examine the prevalence of mutations of the sequestosome 1 gene (SQSTM1) in identified families, and to assess potential genotype-phenotype associations.
We performed a case-control study of patients with Paget's disease and a mutation analysis of the SQSTM1 gene of index patients with familial disease and of the relatives of those with a mutation. Serum alkaline phosphatase (AP) activity was assessed, and bone scintigraphy was performed.
Five percent of patients had at least 1 first-degree relative with the disease, compared with 0.5% of the controls (relative risk 10; 95% confidence interval 1.3-75.6). In 38.9% of patients with familial disease, heterozygous mutations in the SQSTM1 gene were identified. These were the previously described P392L mutation, which was present in 22.2% of patients, and 3 new mutations, S399P, G425R, M404T, 9 of which were present in 3 different families. All mutations were located in the ubiquitin-associated domain of the gene. There was a relationship between serum AP activity, as a marker of the disease, and the presence or absence of the G425R and P392L mutations, the subject's age, and the presence of Paget's disease.
Our data provide further evidence of a causal role of SQSTM1 gene mutations in the pathogenesis of Paget's disease and allow the design of a strategy based on measurements of serum AP activity and age for investigating asymptomatic relatives of patients with familial Paget's disease of bone.
评估荷兰家族性骨Paget病的发生率,检测确诊家族中含缬酪肽蛋白1基因(SQSTM1)突变的患病率,并评估潜在的基因型-表型关联。
我们对Paget病患者进行了病例对照研究,并对家族性疾病的索引患者及其有突变的亲属的SQSTM1基因进行了突变分析。评估血清碱性磷酸酶(AP)活性,并进行骨闪烁显像。
5%的患者至少有1名患该病的一级亲属,而对照组为0.5%(相对危险度10;95%置信区间1.3 - 75.6)。在38.9%的家族性疾病患者中,鉴定出SQSTM1基因的杂合突变。这些是先前描述的P392L突变,存在于22.2%的患者中,以及3个新突变,S399P、G425R、M404T,其中9个存在于3个不同家族中。所有突变均位于该基因的泛素相关结构域。作为疾病标志物的血清AP活性与G425R和P392L突变的有无、受试者年龄以及Paget病的存在之间存在关联。
我们的数据进一步证明了SQSTM1基因突变在Paget病发病机制中的因果作用,并有助于设计一种基于血清AP活性测量和年龄的策略,用于调查家族性骨Paget病患者的无症状亲属。